

complies with Public Law 94–519, which requires annual reports of donations of personal property to public agencies for use in carrying out such purposes as conservation, economic development, education, parks and recreation, public health, and public safety.

B. Annual Reporting Burden

Respondents: 55.

Annual responses: 220.

Burden hours: 330.

Copy of Proposal. A copy of this proposal may be obtained from the General Services Administration, Acquisition Policy Division (MVP), Room 4035, 1800 F Street NW., Washington, DC 20405, or by telephoning (202) 501–4744 or by faxing your request to (202) 501–4067. Please cite OMB Control No. 3090–0112, State Agency Monthly Donation Report of Surplus Property, in all correspondence.

Dated: December 21, 2001.

Michael Carleton,

Chief Information Officer.

[FR Doc. 02–121 Filed 1–2–02; 8:45 am]

BILLING CODE 6820–61–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case:

Shaan F. Munjee, M.S., Wake Forest University School of Medicine: Based on the report of an investigation conducted by the Wake Forest University School of Medicine (WFUSM) and additional analysis conducted by ORI in its oversight review, the U.S. Public Health Service (PHS) found that Shaan F. Munjee, M.S., former research fellow, Department of Cancer Biology at WFUSM, engaged in scientific misconduct by falsifying and fabricating data in research supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), grants 5 R29 DK52623–03 and 5 R29 DK52623–04, “PTHR and prostate growth.”

Specifically, PHS found that Ms. Munjee falsified data relating to the signaling of protein kinase in prostate

cancer cell lines. From March 2000 through October 2000, Ms. Munjee falsified and fabricated data in her notebook from experiments to misrepresent her productivity and the significance of her findings. Ms. Munjee reported the falsified and fabricated data in: (1) Laboratory group meetings, a journal club, and a Cancer Biology retreat within WFUSM; (2) NIH grant application 5 R29 DK52623–04, “PTHR and prostate growth”; and (3) an abstract submitted to the American Association for Cancer Research. Given the extensive nature of Ms. Munjee’s data falsification and fabrication, none of her research can be considered reliable. Her actions adversely and materially affected the laboratory’s ongoing research in prostate cancer by causing an unproductive avenue of research to be pursued and by preventing the principal investigator from submitting a competitive renewal application for a NIH grant. No publications required correction or retraction.

Ms. Munjee has entered into a Voluntary Exclusion Agreement in which she has voluntarily agreed for a period of three (3) years, beginning on December 17, 2001:

(1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (e.g., grants and cooperative agreements) of the United States Government as defined in 45 CFR Part 76 (Debarment Regulations); and

(2) to exclude herself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative Oversight, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Director, Office of Research Integrity.

[FR Doc. 02–25 Filed 1–2–02; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committees; Tentative Schedule of Meetings for 2002

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for 2002. During 1991, at the request of the Commissioner of Food and Drugs (the Commissioner), the Institute of Medicine (the IOM) conducted a study of the use of FDA’s advisory committees. In its final report, one of the IOM’s recommendations was for the agency to publish an annual tentative schedule of its meetings in the **Federal Register**. This publication implements the IOM’s recommendation.

FOR FURTHER INFORMATION CONTACT:

Linda Ann Sherman, Advisory Committee Oversight and Management Staff (HF–4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1220.

SUPPLEMENTARY INFORMATION: The IOM, at the request of the Commissioner, undertook a study of the use of FDA’s advisory committees. In its final report in 1992, one of the IOM’s recommendations was for FDA to adopt a policy of publishing an advance yearly schedule of its upcoming public advisory committee meetings in the **Federal Register**; FDA has implemented this recommendation. The annual publication of tentatively scheduled advisory committee meetings will provide both advisory committee members and the public with the opportunity, in advance, to schedule attendance at FDA’s upcoming advisory committee meetings. Because the schedule is tentative, amendments to this notice will not be published in the **Federal Register**. However, changes to the schedule will be posted on the FDA advisory committees’ Web site located at <http://www.fda.gov/oc/advisory/default.htm>. FDA will continue to publish a **Federal Register** notice 15 days in advance of each upcoming advisory committee meeting to announce the meeting (21 CFR 14.20).

The following list announces FDA’s tentatively scheduled advisory committee meetings for 2002. You may also obtain up-to-date meeting information by calling the Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area):

Committee Name	Dates of Meetings	Advisory Committee 5-Digit Information Line Code
OFFICE OF THE COMMISSIONER		
Science Board to the Food and Drug Administration	April 16, November 12	12603
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH		
Allergenic Products Advisory Committee	March 15, November 4	12388
Biological Response Modifiers Advisory Committee	February 28–March 1 (Alternate: January 30–31), July 18–19 (Alternate: May 9–10), November 7–8 (Alternate: October 10–11).	12389
Blood Products Advisory Committee	March 14–15, June 13–14, September 12–13, December 12–13.	19516
Transmissible Spongiform Encephalopathies Advisory Com- mittee.	January 16–17, June 26–27, October 17–18	12932
Vaccines and Related Biological Products Advisory Committee	January 30–31, March 6–7, May 21–22, July 10– 11, September 10–11, November 18–19.	12391
CENTER FOR DRUG EVALUATION AND RESEARCH		
Advisory Committee for Pharmaceutical Science	February 25–26, May 7–9, October 23–25	12539
Advisory Committee for Reproductive Health Drugs	September 13	12537
Anesthetic and Life Support Drugs Advisory Committee	January 30–31, April 11–12	12529
Anti-Infective Drugs Advisory Committee	February 19–20	12530
Antiviral Drugs Advisory Committee	January 24, March 19, June 24–25, October 16– 17.	12531
Arthritis Advisory Committee	February 19–20, May 14–15, July 29–30, Sep- tember 12–13, December 10–11.	12532
Cardiovascular and Renal Drugs Advisory Committee	January 17–18, April 11–12, July 18–19, October 10–11.	12533
Dermatologic and Ophthalmic Drugs Advisory Committee	September 20	12534
Drug Abuse Advisory Committee	No meetings planned	12535
Endocrinologic and Metabolic Drugs Advisory Committee	March 14–15, May 23–24, July 22–23, Sep- tember 26–27, December 5–6.	12536
Gastrointestinal Drugs Advisory Committee	September 27	12538
Medical Imaging Drugs Advisory Committee	April 18, August 15	12540
Nonprescription Drugs Advisory Committee	April 22–23	12541
Oncologic Drugs Advisory Committee	January 31, February 27–28, June 6–7	12542
Peripheral and Central Nervous System Drugs Advisory Com- mittee.	February 15	12543
Pharmacy Compounding Advisory Committee	September 27	12440
Psychopharmacologic Drugs Advisory Committee	September 13	12544
Pulmonary-Allergy Drugs Advisory Committee	January 17–18, May 16–17	12545
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION		
Food Advisory Committee	June 4–5, September 24–25	10564
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH		
Device Good Manufacturing Practice Advisory Committee	No meetings planned	12398
Medical Devices Advisory Committee:		

Committee Name	Dates of Meetings	Advisory Committee 5-Digit Information Line Code
Anesthesiology and Respiratory Therapy Devices Panel	March 18, May 13, September 23, October 28	12624
Circulatory System Devices Panel	March 4–5, June 3–4, September 9–10, November 4–5, December 2–3.	12625
Clinical Chemistry and Clinical Toxicology Devices Panel	February 11–12, May 23–24, August 19–20, November 8.	12514
Dental Products Panel	May 9–10, August 22–23, October 29–30	12518
Ear, Nose, and Throat Devices Panel	February 21–22, April 25–26, June 20–21, August 15–16, October 17–18, December 12–13.	12522
Gastroenterology and Urology Devices Panel	February 1, May 17, August 9, November 7	12523
General and Plastic Surgery Devices Panel	February 7–8, April 9–10, July 8–9, October 1–2	12519
General Hospital and Personal Use Devices Panel	March 11–12, June 10–11, September 9–10, December 5–6.	12520
Hematology and Pathology Devices Panel	April 15–16, June 17–18, September 26–27	12515
Immunology Devices Panel	March 15, June 14, September 13, December 6	12516
Medical Devices Dispute Resolution Panel	As needed	10232
Microbiology Devices Panel	February 21–22, May 9–10, September 19–20, October 28–29.	12517
Molecular and Clinical Genetics Panel	April 19, July 26, November 1	10231
Neurological Devices Panel	February 25–26, May 9–10, August 1–2, November 21–22.	12513
Obstetrics and Gynecology Devices Panel	April 22–23, July 22–23, October 21–22	12524
Ophthalmic Devices Panel	January 17–18, March 14–15, May 16–17, July 18–19, September 12–13, November 14–15.	12396
Orthopaedic and Rehabilitation Devices Panel	January 10, April 11–12, July 11–12, October 17–18.	12521
Radiological Devices Panel	February 4, May 20, August 12, November 18	12526
National Mammography Quality Assurance Advisory Committee	May 6, September 23	12397
Technical Electronic Product Radiation Safety Standards Committee.	May 15	12399
CENTER FOR VETERINARY MEDICINE		
Veterinary Medicine Advisory Committee	January 22–24, September 16	12548
NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH		
Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants.	March 13–14, September 24–25	12560
Science Advisory Board to the National Center for Toxicological Research.	June 11–12	12559

Dated: December 26, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 02-26 Filed 1-2-02; 8:45 am]

BILLING CODE 4160-02-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Joint Meeting of the Transmissible Spongiform Encephalopathies Advisory Committee and the Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming joint meeting of two public advisory committees of the Food and Drug Administration (FDA). At least one portion of the joint meeting will be closed to the public.

Name of Committees: Transmissible Spongiform Encephalopathies Advisory Committee and the Blood Products Advisory Committee.

General Function of the Committees: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on January 16, 2002, from 1 p.m. to 4:30 p.m.; and on January 17, 2002, from 8 a.m. to 5:15 p.m.

Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact: William Freas or Sheila D. Langford, Center for Biologics Evaluation and Research (HFM-71), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12392. Please call the Information Line for up-to-date information on this meeting.

Agenda: On January 17, 2002, the committees will listen to updates on the "Revised FDA Guidance on Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products" document, and other related topics. For the purpose of further evaluating the adequacy of our present blood deferral recommendations, the committee will then discuss the effectiveness of measures taken to protect humans from foodborne exposure to the bovine spongiform

encephalopathy (BSE) agent in countries with BSE.

Procedure: On January 17, 2002, from 8 a.m. to 4 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 11, 2002. Oral presentations from the public will be scheduled between approximately 1:20 p.m. and 2:20 p.m. on January 17, 2002. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 11, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On January 16, 2002, from 1 p.m. to 4 p.m., the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). This portion of the meeting will be closed to permit discussion of this material.

FDA regrets that it was unable to publish this notice 15 days prior to the January 16 and 17, 2002, Joint Meeting of the Transmissible Spongiform Encephalopathies Advisory Committee and the Blood Products Advisory Committee meeting. Because the agency believes there is some urgency to bring these issues to public discussion and qualified members of the Joint Meeting of the Transmissible Spongiform Encephalopathies Advisory Committee and the Blood Products Advisory Committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 26, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 02-45 Filed 1-2-02; 8:45 am]

BILLING CODE 4160-02-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

XAGE-1, A Gene Expressed in Multiple Cancers and Uses Thereof

Drs. Ira H. Pastan (NCI), Xiu F. Liu (NCI), Byungkook Lee (NCI) and Lee J. Helman (NCI)

DHHS Ref. No. E-161-00/0 (Provisional Application) filed September 1, 2000 and E-161-00/1 (PCT Application) filed August 31, 2001

Licensing Contact: Richard Rodriguez; 301/496-7056 ext. 287; e-mail: rodrigur@od.nih.gov.

The XAGE-1 gene is a human X-linked gene that is strongly expressed in breast cancer, lung cancer and several other cancers as well as normal testes. The largest open reading frame of the XAGE-1 transcript encodes a putative protein of 16.3 kD (p16) with a potential transmembrane domain at the amino terminus. In addition, the XAGE-1 transcript contains a second ATG in the reading frame corresponding to residue 66, which would encode a 9 kD protein (p9). *In vitro* transfection experiments using 293 T cells have revealed a 9 kD protein. However, the size of the endogenously expressed protein is not yet known. XAGE-1 shares homology with GAGE/PAGE proteins in the C-terminal end.